GeNeuro to Present New Data Supporting Role of Human Endogenous Retroviruses in Type 1 Diabetes at American Diabetes Association’s (ADA) 78th Scientific Sessions

GENEVA--()--Regulatory News:

GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis (MS) and type 1 diabetes (T1D), today announced that it will present new data supporting the role of the human endogenous retrovirus protein, pHERV-W Env, in T1D pathogenesis at the upcoming American Diabetes Association’s 78th Scientific Sessions, being held June 22-26, 2018 in Orlando, Florida. GeNeuro is currently conducting a Phase IIa study (RAINBOW) with GNbAC1, a monoclonal antibody targeting pHERV-W Env in 60 patients with T1D. Initial 6-months results are expected by the end of September 2018.

Poster Details:

Title: “HERV-W-Env involvement in human T1D pathogenesis: New insights from two mouse models”

Lead Author: Sandrine Levet
Poster Session/Section: Pediatrics-type 1 diabetes
Location: Orlando, Fl, USA
Date: Monday, June 25
Time: 11am-1pm

The poster will be available on the GeNeuro website at the start of the poster session.

In addition, GeNeuro’s scientific team and Australian investigators have published details of the Phase IIa study in the peer-reviewed journal, Diabetes, Obesity and Metabolism. The paper, titled “A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti‐HERV‐W‐Env monoclonal antibody”, provides an overview on the discovery and preclinical development of GNbAC1 as a new investigational treatment for T1D as well as a detailed description of the design of the current Phase IIa RAINBOW study in Australia. For more information, click here.

About Type 1 Diabetes

Type 1 diabetes, usually first diagnosed in children, is caused by an immune response directed against the insulin producing cells of the pancreas. There is no cure for this ‘autoimmune’ disease, which means patients need life-long treatment with insulin replacement. This treatment is often associated with several debilitating complications, including heart disease, blindness, and kidney disease, among others.

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 29 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com

Disclaimer

This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 4800
investors@geneuro.com
or
NewCap (France)
Julien Perez (investors)
+33 1 44 71 98 52
or
Nicolas Merigeau (media)
+33 1 44 71 94 98
geneuro@newcap.eu
or
Halsin Partners
Mike Sinclair (media)
+44 20 7318 2955
msinclair@halsin.com
or
LifeSci Advisors
Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com

Contacts

GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 4800
investors@geneuro.com
or
NewCap (France)
Julien Perez (investors)
+33 1 44 71 98 52
or
Nicolas Merigeau (media)
+33 1 44 71 94 98
geneuro@newcap.eu
or
Halsin Partners
Mike Sinclair (media)
+44 20 7318 2955
msinclair@halsin.com
or
LifeSci Advisors
Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com